Log In
Print
BCIQ
Print
Print this Print this
 

Incivek, Incivo, Telavic, telaprevir (MP-424, VX-950)

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionSmall molecule HCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 2 infection; Treat HCV genotype 1 infection; Treat HCV genotype 1 infection in patients co-infected with HIV-1; Treat HCV genotype 1 infection in patients who failed previous therapy; Treat HCV genotype 1 infection in treatment-naïve patients; Treat HCV infection; Treat HCV infection in post-liver transplant patients
Regulatory Designation

U.S. - Fast Track (Treat HCV infection);
U.S. - Priority Review (Treat HCV infection);
EU - Accelerated Assessment (Treat HCV genotype 1 infection)

Partner

Johnson & Johnson; Mitsubishi Tanabe Pharma Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today